江苏南方卫材医药股份有限公司 （一）出席会议情况 2024 年度，公司共召开了 5 次董事会，本人均以通讯方式亲自出席会议； 召开了 1 次年度股东大会，本人因有其他工作安排，本人请假未出席过本年度公 司股东会会议。本人现担任南卫股份第四届董事会提名委员会主任委员、薪酬与 考核委员会委员。2024 年公司董事会专门委员会召开提名委员会 1 次会议、薪 酬与考核委员会 1 次会议。 本人均按照规定出席了会议，不存在缺席和委托其他董事出席董事会的情 况。作为公司独立董事根据有关规定，充分发挥自身专业能力，依法履行职责， 对年度内董事会及所任专门委员会审议的议题进行充分的审阅和讨论，发表专业 意见，行使表决权。内容涉及公司内部控制、授信担保事项、利润分配、日常关 联交易、聘请审计机构、董事高级管理人员薪酬等。 报告期内，公司未出现需独立董事行使特别职权的事项。 一、独立董事基本情况 作为南卫股份的独立董事，本人与南卫股份之间不存在雇佣关系、交易关系， 与南卫股份持股 5%以上股东、董监高不存在亲属关系，不存在影响独立性的情 况。 二、独立董事年度履职情况 2024 年度独立董事述职报告 按照《中华人民共和国公司法》 ...

公司代码：603880 公司简称：南卫股份 江苏南方卫材医药股份有限公司 2024年度内部控制评价报告 江苏南方卫材医药股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变 ...

证券代码：603880 证券简称：南卫股份 公告编号：2025-007 江苏南方卫材医药股份有限公司 关于公司会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 本次会计政策变更是依据财政部颁布及修订的会计准则要求，对江苏南方卫 材医药股份有限公司（以下简称"公司"）的会计政策和相关财务信息进行的相应 变更和调整，无需提交公司董事会、股东大会审议。 本次会计政策变更不涉及对公司以前年度的重大追溯调整，不会对公司的损 益、总资产、净资产等财务状况、经营成果和现金流量产生重大影响，亦不存在损 害公司及股东利益的情况。 一、会计政策变更概述 2023 年 10 月 25 日，财政部发布了《企业会计准则解释第 17 号》（财会 〔2023〕21 号），涉及①流动负债与非流动负债的划分；②供应商融资安排的披 露；③售后租回交易的会计处理；其中①、②自 2024 年 1 月 1 日起施行，③自 2024 年 1 月 1 日起施行，也可以选择自发布年度起施行。 本次会计政策变更事项属于根据法律、行政法规 ...

江苏南方卫材医药股份有限公司 对会计师事务所2024年度履职情况评估报告 江苏南方卫材医药股份有限公司（以下简称"公司"）聘请天衡会计师事务 所（特殊普通合伙）（以下简称"天衡所"）作为公司2024年度年报审计机构。 根据财政部、国资委及证监会颁布的《国有企业、上市公司选聘会计师事务所管 理办法》，公司对天衡所2024年审计过程中的履职情况进行评估。经评估，公司 认为天衡所资质等方面合规有效，履职保持独立性，勤勉尽责，公允表达意见， 具体情况如下： 一、资质条件 天衡所于1985年成立，2013年完成改制，从有限责任制事务所转制为特殊普 通合伙制事务所。天衡所总部设在南京，注册地址为南京市建邺区江东中路106 号1907室。截至2024年末，天衡所拥有合伙人85人，执业注册会计师386人。签 署过证券服务业务审计报告的注册会计师227名。天衡所2024年度业务收入总额 为52,937.55万元（人民币，下同），审计业务收入为46,009.42万元，证券业务 收入为15,518.61万元。 二、执业记录 天衡会计师事务所近三年因执业行为受到刑事处罚0次、行政处罚3次、监督 管理措施6次、自律监管措施6次和纪律处 ...

证券代码：603880 证券简称：南卫股份 公告编号：2025-012 江苏南方卫材医药股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 20 日 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2024年年度股东大会 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 5 月 20 日 14 点 45 分 召开地点：江苏省常州市武进经济开发区果香路 1 号江苏南方卫材医药股份 有限公司会议室 股东大会召开日期：2025年5月20日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 至2025 年 5 月 20 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 ...

证券代码：603880 证券简称：南卫股份 公告编号：2025-004 江苏南方卫材医药股份有限公司 第四届监事会第十五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 江苏南方卫材医药股份有限公司（以下简称"公司"）第四届监事会第十五 次会议于 2025 年 4 月 29 日在公司会议室举行，本次会议采取现场表决的方式召 开。本次会议通知于 2025 年 4 月 18 日以书面、电话和电子邮件方式通知了全体 监事。会议应出席监事 3 人，实际出席监事 3 人。本次会议的通知、召开及审议 程序符合《公司法》、《证券法》等法律法规及《公司章程》的有关规定，所作决 议合法有效。 二、监事会会议审议情况 1、审议通过《公司 2024 年年度报告及其摘要》 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）发布的《江 苏南方卫材医药股份有限公司 2024 年年度报告》及《江苏南方卫材医药股份有 限公司 2024 年年度报告摘要》。 4、审议通过《公司 2024 年度利润 ...

证券代码：603880 证券简称：南卫股份 公告编号：2025-003 江苏南方卫材医药股份有限公司 第四届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 江苏南方卫材医药股份有限公司（以下简称"公司"）第四届董事会第十八 次会议于 2025 年 4 月 29 日在公司会议室举行，本次会议采取现场表决与通讯表 决结合的方式召开。本次会议通知于 2025 年 4 月 18 日以书面、电话和电子邮件 方式通知了全体董事。会议应出席董事 7 人，实际出席董事 7 人。本次会议的通 知、召开及审议程序符合《公司法》、《证券法》等法律法规及《公司章程》的有 关规定，所作决议合法有效。 二、董事会会议审议情况 1、审议通过《公司 2024 年年度报告及其摘要》 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）发布的《江 苏南方卫材医药股份有限公司 2024 年年度报告》及《江苏南方卫材医药股份有 限公司 2024 年年度报告摘要》。 该议案在提交公司董事会审 ...

证券代码：603880 证券简称：南卫股份 公告编号：2025-005 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 江苏南方卫材医药股份有限公司（以下简称"公司"）2024 年度的利润分配 预案为：不进行利润分配，也不进行资本公积金转增股本和其他形式的分配。 本次利润分配预案已经公司第四届董事会第十八次会议、第四届监事会第十 五次会议审议通过，尚需提交公司 2024 年年度股东大会审议。 公司不触及《上海证券交易所股票上市规则（2024 年 4 月修订）》（以下简称 《股票上市规则》）第 9.8.1 条第一款第（八）项规定的可能被实施其他风险警示的情 形。 一、利润分配预案内容 经天衡会计师事务所（特殊普通合伙）审计，截止 2024 年 12 月 31 日，公司 2024 年度合并报表归属上市公司股东净利润为-190,668,979.26 元，母公司实现净利润 -29,330,281.53 元，根据《公司法》和《公司章程》的有关规定，当年不计提盈余公积， 加 上 年 初 未 分 配 利 润 167,6 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥170,922,078.18, representing a 22.81% increase compared to ¥139,180,514.20 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥7,917,932.55, a decrease of 553.73% from a profit of ¥1,745,086.17 in the previous year[4] - The basic and diluted earnings per share were both -¥0.027, reflecting a decrease of 550.00% from ¥0.006 in the previous year[4] - The company's operating profit for the first quarter of 2025 was -8,022,705.81 RMB, compared to a profit of 992,605.52 RMB in the same period of 2024, indicating a significant decline[17] - Net profit for the first quarter of 2025 was -7,885,264.56 RMB, while in the first quarter of 2024, it was 1,752,439.19 RMB, reflecting a year-over-year decrease[17] - The company reported a total comprehensive income of -7,885,264.56 RMB for the first quarter of 2025, compared to 1,752,439.19 RMB in the same period of 2024, reflecting overall financial challenges[18] Cash Flow and Liquidity - The net cash flow from operating activities improved to ¥7,452,517.90, a significant increase of 189.86% compared to a negative cash flow of ¥8,293,570.72 last year[4] - The cash and cash equivalents at the end of the first quarter of 2025 were 19,870,011.98 RMB, compared to 17,393,676.52 RMB at the end of the first quarter of 2024, indicating an increase in liquidity[23] - The company's total cash outflow from investing activities for the first quarter of 2025 was -4,037,316.31 RMB, an improvement from -14,359,402.21 RMB in the same period of 2024, suggesting better investment management[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,038,259,496.21, down 1.73% from ¥1,056,553,004.60 at the end of the previous year[5] - The company's total liabilities decreased to RMB 761,089,984.08 from RMB 772,141,846.66 in the previous period[14] - As of March 31, 2025, total current assets amounted to RMB 392,443,866.70, a slight decrease from RMB 400,280,555.09 as of December 31, 2024[12] Shareholder Equity - Shareholder equity attributable to the company decreased by 2.82% to ¥271,401,379.57 from ¥279,286,644.13 at the end of the previous year[5] - The company had a total of 9,737 common shareholders at the end of the reporting period[8] Revenue and Costs - The total operating costs for Q1 2025 were RMB 182,129,434.69, up from RMB 143,955,213.47 in Q1 2024, reflecting a significant increase in expenses[16] - The increase in operating revenue was primarily due to an overall increase in product sales, although some products experienced price declines due to market competition[7] - The total revenue for the first quarter of 2025 was 168,143,580.99 RMB, an increase from 133,298,618.83 RMB in the first quarter of 2024, representing a growth of approximately 26.1%[20] Investments and Expenses - The long-term equity investments increased to RMB 66,408,440.07 from RMB 63,109,513.51[12] - Research and development expenses for the first quarter of 2025 were 6,177,349.18 RMB, slightly down from 6,652,533.16 RMB in the same period of 2024, indicating a focus on cost management[17] - The company incurred financial expenses of 5,102,755.39 RMB in the first quarter of 2025, a significant increase from 1,318,802.03 RMB in the first quarter of 2024, highlighting rising interest costs[17] Inventory and Receivables - The inventory decreased to RMB 173,339,039.73 from RMB 188,896,130.48, indicating a reduction in stock levels[12] - The company reported a significant increase in accounts receivable, rising to RMB 132,382,068.63 from RMB 104,896,317.55, indicating potential growth in sales but also increased credit risk[12]

Financial Performance - The company's total revenue for 2024 was CNY 602,615,333.02, a slight increase of 0.42% compared to CNY 600,095,343.68 in 2023[24]. - The net profit attributable to shareholders for 2024 was a loss of CNY 190,668,979.26, representing a decline of 29.34% from a loss of CNY 147,417,266.38 in 2023[24]. - The basic earnings per share for 2024 was -CNY 0.66, a decrease of 29.41% from -CNY 0.51 in 2023[25]. - The net profit attributable to shareholders of the parent company was CNY -190.67 million, a decrease of CNY 43.25 million year-on-year[33]. - The company achieved operating revenue of CNY 602.62 million in 2024, an increase of CNY 2.52 million compared to the same period last year[33]. - Operating costs rose to 616.73 million yuan, reflecting a 13.28% increase due to higher sales volume[57]. - The company reported a net profit of -31.82 million RMB for its subsidiary, Southern Meibang, indicating ongoing financial challenges[98]. Cash Flow and Assets - The net cash flow from operating activities increased significantly to CNY 63,320,497.91, up 308.27% from CNY 15,509,532.60 in the previous year[24]. - The company's total assets decreased by 17.28% to CNY 1,056,553,004.60 at the end of 2024, down from CNY 1,277,326,306.30 in 2023[24]. - The net assets attributable to shareholders fell by 40.48% to CNY 279,286,644.13, compared to CNY 469,268,077.30 at the end of 2023[24]. - The company reported a net cash flow from operating activities of CNY 56.82 million in the fourth quarter[28]. Market and Competition - The decline in net profit was attributed to increased market competition, price drops, and rising raw material costs for nitrile gloves[26]. - The company reported that product sales volume increased, but overall revenue was affected by price fluctuations in the industry[26]. - The traditional medical consumables market is expected to exceed CNY 220 billion by 2025, driven by national policies and increasing demand[35]. - The traditional medical supplies market is projected to exceed 220 billion RMB, driven by a 15% annual increase in demand for emergency equipment[37]. - The export value of medical supplies is anticipated to reach 80 billion RMB in 2025, reflecting a 15% year-on-year growth[37]. Research and Development - Research and development expenses amounted to CNY 28.72 million, representing a 1.92% increase from the previous year, focusing on transdermal drug delivery technology and process upgrades[34]. - The company holds 16 invention patents, 73 utility models, and 9 design patents, enhancing its competitive edge in technology development[34]. - The company established a new R&D center in collaboration with Zhejiang University, focusing on transdermal drug delivery technologies[50]. - The company is focusing on R&D, production, and sales of transdermal products, medical adhesive tapes, emergency kits, and protective supplies[38]. Operational Efficiency - The company has effectively reduced operational risks and improved internal control management during the reporting period[33]. - The company is focused on optimizing production management to enhance core competitiveness and reduce costs[34]. - The company employs an "order-based" production model, ensuring production aligns with customer demand[46]. - The company emphasizes technological R&D, continuously upgrading equipment and processes to maintain competitive advantages[49]. Governance and Management - The management team has extensive experience and has established a standardized management system covering all operational aspects[52]. - The company has a diverse board of directors with expertise in law, finance, and management[128]. - The overall management structure supports the company's long-term growth strategy[128]. - The company plans to optimize its governance structure and improve internal control management systems to ensure compliance and efficiency[104]. Shareholder and Investor Relations - The company plans to apply for comprehensive credit facilities from banks and other financial institutions for the year 2024[125]. - The company has a cash dividend policy that mandates a minimum of 25% of distributable profits to be distributed as cash dividends when conditions allow[151]. - The company did not propose any cash profit distribution plan despite having a positive profit available for distribution to shareholders, and it must disclose the reasons and usage plans for undistributed profits[155]. - The company emphasizes investor relations and maintains transparent communication with stakeholders to protect their interests and enhance sustainable development[122]. Environmental and Social Responsibility - The company invested 1.52 million RMB in environmental protection during the reporting period[162]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[164]. - The company adheres to national environmental laws and regulations, actively managing environmental facilities and emissions[166]. - There are no separate disclosures for social responsibility or sustainability reports during the reporting period[168]. Legal and Compliance Issues - The company received a notice from the China Securities Regulatory Commission regarding suspected violations of information disclosure laws[182]. - The company has reported a 20% decrease in audit fees compared to the previous year[177]. - The company is involved in significant litigation matters, including disputes with Beijing Sentai Weiye International Trade Co., with a claim amount of 487.10 million RMB[180]. - The company has made provisions for bad debts amounting to 459.31 million RMB related to the litigation with Beijing Sentai Weiye International Trade Co.[180]. Future Outlook and Strategy - The company aims to enhance the profitability of its main products and control production costs and expenses by 2025[102]. - The company is actively pursuing market expansion through the development of new medical products and technologies, aiming to enhance its competitive position in the industry[93]. - The company plans to explore the development of more emergency series products for various fields, including family, traffic accidents, and natural disasters[85]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of 100 million allocated for potential deals[130].